Island Pharmaceuticals (ASX: ILA)
We spoke with David Foster, CEO of Island Pharmaceuticals (ASX: ILA), about the great data the company has just received from its Phase 2a study of ILA-101 in dengue fever.
The study generated highly encouraging top-line results showing that ISLA-101 associated with meaningful reduction in both viral load and symptoms in preventative cohort.
ILA is now planning the next clinical study. In an environent where dengue is now starting to show up in all sorts of places where it hasn’t been endemic, Island Pharmaceuticals’ data is timely.
Disclosure: ILA is a research client of Pitt Street Research. Check out our research coverage on ILA here!
Looking for the Best ASX Life Sciences stocks to invest in right now?
